Clinical evidence suggests that the FLT3 mutation may occur in a sub-clone of the leukemia stem cell (LSC), including the finding that in the context of relapsed AML, there is loss of the ITD mutation 16% of the time and loss of the TKD mutation 50% of the time [21,22]. Here, FLT3 is linked to leukemia.